Non-small Cell Lung Cancer Metastatic Clinical Trial
Official title:
Registry of Guardant360® Use and Outcomes In People With Advanced Cancer
The purpose of this registry is to collect data that describes the characteristics of people with advanced cancer for whom the Guardant360 assay is ordered and to observe their clinical outcomes after receiving their results.
This is a prospective, descriptive registry of people with advanced cancer for whom a
Guardant360 assay has been ordered by their health care providers. The registry is divided
into modules according to primary cancer diagnosis. Module 1 includes subjects with advanced
NSCLC with additional modules added later in the study.
All eligible people for whom blood for a Guardant360 assay has been collected will be invited
to participate in the registry. Subject demographics and relevant medical history will be
collected at the time of enrollment. Information on tumor molecular testing, treatment
decisions, and clinical outcomes from the time of enrollment will be collected in a
prospective manner. The registry does not require any specific treatments or procedures but
rather collects information on the treatment journey of each participant. Subjects may
participate in other clinical studies while also participating in GEODE.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01523340 -
A Prospective Observational Study Evaluating c-MET Expression and EGFR Gene Mutation Correlation With Erlotinib Response
|
||
Recruiting |
NCT03956641 -
Evolution of the Physical Condition in Treated Cancer Patients
|
N/A | |
Active, not recruiting |
NCT02035683 -
PET/CT Scan as a Tool to Rationalize the Treatment of of Advanced NSCLC Patients Undergoing First Chemotherapy
|
N/A | |
Completed |
NCT01848613 -
Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC
|
Phase 4 | |
Suspended |
NCT01320501 -
Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer
|
Phase 4 | |
Terminated |
NCT01471964 -
Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT06127940 -
K-SAB Trial - Sotorasib Followed by SBRT to 1-3 Lesions in Advanced NSCLC With KRASG12C Mutation
|
Phase 1 | |
Terminated |
NCT04069936 -
Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC
|
Phase 2 | |
Terminated |
NCT03445000 -
ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT03386929 -
Survival Prolongation by Rationale Innovative Genomics
|
Phase 1/Phase 2 | |
Recruiting |
NCT02922764 -
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
|
Phase 1 | |
Terminated |
NCT01574300 -
Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network
|
||
Active, not recruiting |
NCT04646824 -
Almonertinib With Chemotherapy in mEGFR NSCLC
|
Phase 2 | |
Completed |
NCT01966003 -
Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer
|
Phase 3 | |
Recruiting |
NCT03656094 -
Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors
|
Phase 2 | |
Terminated |
NCT01348126 -
Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT03469960 -
Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr
|
Phase 3 | |
Recruiting |
NCT05919264 -
FOG-001 in Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT04793815 -
Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE)
|
N/A | |
Terminated |
NCT01380795 -
Feasibility of the Research for Mutation of K-ras and EGFR in CTCs From Metastatic Non Small Cells Bronchial Carcinomas
|
Early Phase 1 |